Infusion of Prostacyclin vs Placebo for 72-hours in Mechanically Ventilated Patients With Acute Respiratory Failure (COMBAT-ARF)
Efficacy and Safety of 72-hour Infusion of Prostacyclin (1 ng/kg/Min) in Mechanically Ventilated Patients With Infectious Pulmonary Endotheliopathy - a Multicenter Randomized, Placebo-controlled, Blinded, Investigator-initiated Trial
Sponsor: Pär Johansson
Listed as NCT06319274, this PHASE2 trial focuses on Acute Respiratory Failure and Endothelial Dysfunction and remains actively recruiting participants. Sponsored by Pär Johansson, it has been updated 7 times since 2024, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Recruiting PHASE2
-
Jul 2025 — Sep 2025 [monthly]
Recruiting PHASE2
-
Dec 2024 — Jul 2025 [monthly]
Recruiting PHASE2
-
Sep 2024 — Dec 2024 [monthly]
Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2
▶ Show 2 earlier versions
-
Jun 2024 — Jul 2024 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Apr 2024 — Jun 2024 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Pär Johansson
For direct contact, visit the study record on ClinicalTrials.gov .